Study on the Prevention of Atrial Fibrillation Recurrence After Ablation by Qidong Yixin Granule
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 846 participants.
Also called NCT07508618
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 846 participants
- Registry
-
NCT07508618
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07508618. Randomized; quadruple masking; primary purpose prevention. Start 2026-02-09 (actual); primary completion 2027-08-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study on the Prevention of Atrial Fibrillation Recurrence After Ablation by Qidong Yixin Granule
- Acronym
- QDYX-AF
- Condition
- Persistent Atrial Fibrillation
- Intervention (Drug)
- Qi Dong Yi Xin Granules
- Intervention (Drug)
- Placebo
- Lead sponsor
- Sir Run Run Shaw Hospital
- Collaborator
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct07508618- Content hash
76f5d1a6c1160d42e4bb1b45a22ee17fa2910d0ee6350b6f56e22af938b43a34